Lana Pine is the editor of HCPLive Rheumatology. She is an experienced editor and technical writer with a demonstrated history of working in the banking and publishing industries. In her free time, she enjoys cooking, yoga, listening to podcasts, and drawing. She can be reached via email at LPine@mjhlifesciences.com.
Etanercept Shows Greater Improvements in Treating Psoriatic Arthritis Than MTX MonotherapyFebruary 5th 2021
In this 48-week, phase 3, randomized controlled trial, investigators examined patient-reported outcomes of patients with psoriatic arthritis receiving methotrexate monotherapy, etanercept monotherapy, or a combination of both drugs.
Tocilizumab Does Not Improve Outcomes for Patients With Severe COVID-19February 3rd 2021
Tocilizumab is an interleukin 6 (an inflammatory cytokine) inhibitor approved for treating a variety of rheumatic diseases, including rheumatoid arthritis. As studies have shown that an increased level of interleukin 6 directly correlates to poor COVID-19 outcomes, investigators speculated that blocking this activity could be a helpful tool in treating the virus and lessening its severity.
Alice Fike, MS, NP: Latino Patients Disproportionately Affected by COVID-19February 2nd 2021
This week, we sat down for an interview with Alice Fike, MS, NP, from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), to discuss her study titled “Risk factors for COVID-19 and rheumatic disease flare in a US cohort of Latino patients.” The primary objective of this retrospective study was to understand why Latino patients were being disproportionately affected by coronavirus disease 2019 (COVID-19).
Latino Patients With Rheumatic Diseases are at Higher Risk of Contracting COVID-19February 1st 2021
The primary objective of this retrospective study was to understand why Latino patients were being disproportionately affected by COVID-19. Of the patients observed, 32 (18%) developed COVID-19 during the study period, meaning incidence rates were 5- to 11-fold higher than the general population (1,540 to 3,431/100,000).
April Jorge, MD: Improved COVID-19 Outcomes for Patients With Rheumatic DiseaseJanuary 29th 2021
This week, we sat down for an interview with April Jorge, MD, to discuss the findings of her study, “Temporal trends and severe COVID-19 outcomes in patients with rheumatic disease,” and what this may mean for patients with rheumatic disease moving forward in the pandemic.
Filgotinib and Methotrexate Combination Therapy Proves Effective Treatment for RA in FINCH 3 TrialJanuary 28th 2021
In a new study, investigators set out to discover whether the Janus kinase-1 inhibitor filgotinib is efficacious, either in combination with MTX or as monotherapy, in patients with RA who have had limited or no MTX exposure.
Study Results Determine No Link Between Hydroxychloroquine and Heart Failure in Patients With Rheumatoid ArthritisJanuary 26th 2021
A recent study published in The Journal of Rheumatology found no association between hydroxychloroquine therapy and heart failure in patients with rheumatoid arthritis (RA) and other rheumatic diseases, such as systemic lupus erythematous (SLE).
Elderly Multimorbidity Clinic Model Offers No Sustained Benefit for Patients With Rheumatoid ArthritisJanuary 21st 2021
Investigators aimed to improve the quality of care by creating effective management plans using the goals of both the patient and physician. During the course of the Elderly Multimorbidity Clinic (EMC) program, 75% of patients accomplished at least 1 of their goals. Unfortunately, no sustained benefits were observed because of low follow-up.
Improved COVID-19 Outcomes for Patients With Rheumatic DiseasesJanuary 20th 2021
Investigators found "improved outcomes for patients with rheumatic and musculoskeletal diseases after COVID-19 diagnosis in more recent months of the pandemic compared with earlier months, including lower risks of death, respiratory failure, and renal failure."
Baricitinib 4 Mg Proves Effective for Reducing Joint Damage Progression for Patients with Rheumatoid ArthritisJanuary 13th 2021
Previously proven to be an effective and well-tolerated treatment for patients with RA, baricitinib can also help patients reduce joint damage progression and erosion.
FDA Approves Belimumab as First Lupus Nephritis Drug in USDecember 17th 2020
In this phase 3, 104-week, randomized, double-blind, placebo-controlled, post-approval commitment study, Efficacy and Safety of Belimumab in Adult Patients with Active Lupus Nephritis (BLISS-LN) evaluated the efficacy and safety of intravenous BENLYSTA in conjunction with standard therapy and found that it was more effective than a placebo.